SciClone Pharmaceuticals Inc. (SCLN)

Oncology Corporate Profile

Stock Performance

13.1700
0.0100

HQ Location

950 Tower Lane, Suite 900
Foster City, CA 94404

Company Description

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases. SciClone's strategy is to in-license late-stage clinical products and develop them for commercialization in the United States, Europe, and China, one of the world‰Ûªs fastest growing pharmaceutical markets.

Website: http://www.sciclone.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Zadaxinp_ / thymalfasinimmune system modulatorMelanomaIII
RP101nucleoside analogPancreatic cancerII
PT-112Platinum-based antineoplasticBreast cancerIPhosplatin Therapeutics

View additional information on product candidates here »

Source


http://www.sciclone.com

Recent News Headlines

ASH: Venetoclax, Acalabrutinib Active in Relapsed CLL

12/8/2015 11:02 am

(Physician’s Briefing/HealthDay News) Dec 8, 2015 - Oral venetoclax and acalabrutinib are active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to two studies published online Dec. 7 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in Orlando, Fla.

Multiple Myeloma Patient Study Shows Promise For Natural Killer Cells

12/8/2015 11:02 am

(MD Anderson) Dec 7, 2015 - Phase I study included combination with high-dose chemotherapy and stem cell transplantation.

Studies Highlight New Drug Targets Or Compounds For Acute Myeloid Leukemia

12/8/2015 11:02 am

(Dana-Farber) Dec 7, 2015 - Preclinical data unveiled across four studies presented at the 57th annual meeting of the American Society of Hematology highlight four potential treatment opportunities for acute myeloid leukemia (AML), a blood cancer accounting for approximately 20 percent of all childhood leukemias and 32 percent of adult leukemias.

Genetic Variants Tied To Increased Risk Of Bone Complications In Young Leukemia Patients

12/8/2015 11:02 am

(St. Jude Children’s) Dec 5, 2015 - Gene variants identified that leave young acute lymphoblastic leukemia patients at increased risk for osteonecrosis as a side effect of treatment.

Juno’s Investigational CAR T Cell Product Candidates JCAR015 and JCAR014 Demonstrate Encouraging Clinical Responses in Patients with B-cell Cancers

12/8/2015 11:02 am

(Yahoo! Finance) Dec 7, 2015 - Juno Therapeutics, Inc. today announced, in partnership with its collaborators, that clinical data from separate trials for chimeric antigen receptor (CAR) T cell product candidates, JCAR015 and JCAR014, demonstrated encouraging clinical responses in patients with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL).

Kite Pharma Presents Phase 1 Results From ZUMA-1 at the 57th American Society of Hematology (ASH) Annual Meeting

12/8/2015 11:02 am

(PharmiWeb.com) Dec 7, 2015 - Kite Pharma, Inc. today announced clinical results and biomarker data for the phase 1 portion of Kite's ZUMA-1 trial of KTE-C19 in patients with refractory, aggressive non-Hodgkin lymphoma (NHL).

ERYTECH Announces Presentation of Additional Data at the American Society of Hematology 57th Annual Meeting

12/8/2015 11:02 am

(CNBC) Dec 8, 2015 - ERYTECH Pharma announces that investigators presented additional results from the pivotal Phase 2/3 clinical trial with GRASPA that add to the body of data supporting the potential benefit of GRASPA in combination with chemotherapy in the treatment of Acute Lymphoblastic Leukemia (ALL).

Phase 1 Results Point To Larger Trial Of Enzalutamide And Fulvestrant In Breast Cancer

12/8/2015 11:02 am

(UCCC/Colorado Cancer Blogs) Dec 7, 2015 - Results of a multicenter phase 1 clinical trial presented today at the 2015 San Antonio Breast Cancer Symposium show that the anti-androgen agent enzalutamide is active and well-tolerated alone and with fulvestrant in patients with advanced breast cancer. The study takes another important step toward larger clinical trials targeting androgen receptors in breast cancer.

Loss of Enzyme Promotes Tumor Progression In Endometrial Cancer

12/8/2015 11:02 am

(MD Anderson) Dec 7, 2015 - Scientists have shown for the first time why loss of the enzyme CD73 in human cancer promotes tumor progression.

Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA® (pembrolizumab) Data

12/8/2015 11:01 am

(Merck) Dec 8, 2015 - Merck, known as MSD outside the United States and Canada, announced today that new study findings investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, across a range of hematological cancers were presented at the 57th American Society of Hematology (ASH) Annual Meeting.

Strong Cancer Trial Data For Janssen At ASH 2015

12/8/2015 11:01 am

(Pharmafile [UK]) Dec 8, 2015 - Janssen presented new cancer trial data at the 57th Annual American Society of Haematology (ASH) meeting Orlando, Florida – with study results for Darzalex (daratumumab) proving a highlight.

ASH 2015 Roundup: Amgen, MorphoSys, Novartis and Amgen Present New Trial Data

12/8/2015 11:01 am

(Pharmafile [UK]) Dec 8, 2015 - Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL) - a rare and rapidly progressing cancer of the blood and bone marrow.

Ixazomib in First Oral Triplet for Multiple Myeloma

12/8/2015 07:00 am

(Medscape Medical News) Dec 7, 2015 - The newly approved ixazomib (Ninlaro, Millennium/Takeda) is the first available oral proteasome inhibitor and offers patients with multiple myeloma the option of taking an all-oral treatment regimen.

Phase 3 Results for Zydelig® With Bendamustine and Rituximab for Relapsed Chronic Lymphocytic Leukemia (CLL) Presented at American Society of Hematology Annual Meeting

12/8/2015 07:00 am

(Gilead) Dec 8, 2015 - Study shows statistically significant benefit for Zydelig in progression-free survival.

Officials Rally for an Extension of a 9/11 Health Bill

12/7/2015 06:00 pm

(New York Times) Dec 6, 2015 - Standing in the shadow of the towering rebuilt World Trade Center, scores of firefighters and police officers, led by Mayor Bill de Blasio and two United States senators from New York, rallied on Sunday to press Congress to extend a 9/11 health bill.

SciClone Pharmaceuticals to Present at Jefferies Global Healthcare Conference

5/29/2012 08:00 pm

[Marketwire] - FOSTER CITY, CA-- - SciClone Pharmaceuticals, Inc. today announced that Gary Titus, Chief Financial Officer, will present a corporate overview and business update at the Jefferies Global Healthcare Conference ...

SciClone Increases Stock Repurchase Program

5/29/2012 10:00 am

[Marketwire] - FOSTER CITY, CA-- - SciClone Pharmaceuticals, Inc. today announced that its board of directors has approved an increase of approximately $10.5 million to the Company's stock repurchase program. The increase ...